

Supplementary Information to:

Glycan shield of the ebolavirus envelope glycoprotein GP

Weiwei Peng ¹, Vamseedhar Rayaprolu ^{2,4}, Amar D. Parvate ^{2,5}, Matti F. Pronker ¹, Sean Hui ^{2,6},
Diptiben Parekh ², Kelly Shaffer ^{2,7}, Xiaoying Yu ², Erica O. Saphire ^{2,3}, Joost Snijder ^{1*}

¹ Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute of Pharmaceutical Sciences, Utrecht University, Padualaan 8, 3584 CH Utrecht, The Netherlands

² Center for Infectious Disease and Vaccine Discovery, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.

³ Department of Medicine, University of California, San Diego, La Jolla, CA 92039, USA

⁴ Current affiliation - Pacific Northwest Center for CryoEM, Portland, OR 97225, USA


⁵ Current affiliation - Environmental Molecular Sciences Laboratory, Pacific Northwest National Laboratory, Richland, WA 99354, USA

⁶ Current affiliation – Molecular Microbiology and Microbial Pathogenesis Program, Washington University School of Medicine, Saint Louis, MO 63108, USA


⁷ Current affiliation – Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA


*corresponding author: j.snijder@uu.nl

Supplementary Figures S1-S5



Supplementary Figure S2. Overview of site-specific N-linked glycan processing in ebola virus GPΔTM from HEK293 and S2 cells, versus full-length GP from HEK293 derived VLPs as determined by LC-MS/MS. The glycans were classified by HexNAc content as truncated, paucimannose, high-mannose, hybrid or complex. Shown is the average of a duplicate experiment.





Supplementary Figure S5. MS/MS spectrum of glycopeptide from HEK293-derived BDBV GP Δ TM with O-linked glycosylation in the Strep-tag of the recombinant soluble ectodomain.